Expert consensus on treatment for stage III non‐small cell lung cancer
Yi‐Long Wu(Guangdong Academy of Medical Sciences), Yun Fan(Zhejiang Cancer Hospital), Fang Wu(Central South University), Jianya Zhou(First Affiliated Hospital Zhejiang University), Yukun Kuang(Sun Yat-sen University), Haihong Yang(First Affiliated Hospital of Guangzhou Medical University), Yu Yao(Central South University), Buhai Wang(Northern Jiangsu People's Hospital), Weineng Feng(First People's Hospital of Foshan), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Jiuwei Cui(Jilin University), Lizhu Lin(Guangzhou University of Chinese Medicine), Chao Cheng(Sun Yat-sen University), Ying Cheng(Jilin Province Tumor Hospital), Ming Zhou(Guangzhou Medical University Cancer Hospital), Jian Zhao(ShanghaiTech University), Jiayan Wu(Hong Kong Baptist University), Chengping Hu(Central South University), Shaodong Hong(Sun Yat-sen University), Xiaolong Yan(Southwest University), Xue‐Ning Yang(Guangdong Academy of Medical Sciences), Wenmei Su(Guangdong Medical College), Nong Yang(Central South University), Xiaorong Dong(The University of Melbourne), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Binchao Wang(Northern Jiangsu People's Hospital), Lin Wu(Materials Systems (United States)), Yan Huang(Chinese PLA General Hospital), Chun Chen(Sun Yat-sen University), Lifeng Wang(Nanjing Drum Tower Hospital), Li Zhang(Jinan Stomatological Hospital), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jingjing Liu(Jilin Province Tumor Hospital), Yong Song(Nanjing General Hospital of Nanjing Military Command), Si‐Yang Liu(Sun Yat-sen University), Jie Lin(Kunming Medical University), Hui Guo(Ministry of Education of the People's Republic of China), Jin‐Ji Yang(Guangdong General Hospital), Rongrong Chen(Annoroad Gene Technology (China)), Qinghua Zhou(Sichuan University), Rui Ma(Xijing Hospital), Yongchang Zhang(Central South University), Jia‐Tao Zhang(Guangdong Academy of Medical Sciences), Hongxu Liu(Sun Yat-sen University), Yingying Du(Second Military Medical University), Jia Hu(Wuhan University of Science and Technology), Xueping Quan(Shanghai CASB Biotechnology (China)), Yang Shao(Sanya University), Huijuan Wang(Zhengzhou University), Shun Lü(Shanghai Jiao Tong University)
Cited by 18
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k